Skip to Main Content

Food and Drug Administration Commissioner Scott Gottlieb wants more drugs approved, faster. Toward that goal, the agency is permitting Sage Therapeutics (SAGE) to conduct fewer and shorter clinical trials for its second drug to treat two forms of depression, the biotech said Tuesday.

The accelerated development plan for Sage’s depression pill, called SAGE-217, emerged following a meeting with FDA regulators. If clinical trials are positive, the FDA will allow Sage to seek approval for SAGE-217 to treat major depressive disorder and postpartum depression faster than previously expected.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!